


CASE REPORT

	Normal birth history, developed well till 1 yr.
1 year	Episodic movements → dystonic posturing of the fingers and toes + stops activity. (Video 1) Episodic reduced oral intake due to difficulty in swallowing (? dysphagia) + Irritability
1.5 years	Developed axial dystonia and asymmetric appendicular dystonia Increased severity + frequency of dystonia + ? Decompensation episodes
3 years	Complete regression of milestones Persistent dystonia

FAMILY HISTORY

Eldest Girl	Eldest Boy	2 nd Boy
Normal till 1 year		
Abnormal movement ? Tonic posturing Seizures	Abnormal movements since 11/2 yrs, progressive Regression motor > cognitive, speech	Abnormal movements ? Tonic posturing Seizures
Expired at 2 years ? Cause	At present 6 years Bedridden , no speech, No feeding issues Dystonia No episodic decompensation	Expired at 2 years ? cause





ON EXAMINATION

	PROBAND	ELDER BROTER
Head circumference	Microcephaly	
Anthropometry	Failure to thrive	
Cognition	Recognises parents, eye contact +	No
CNS examination	Spasticity , Dystonia (appendicular > axial) Brisk Reflexes No nystagmus	
	Severe dysphagia	No dysphagia
	Normal cerebellar signs and cranial nerves	
Other system examination	Normal	

INVESTIGATION

Basic blood, metabolic , ophthalmic evaluation in Proband	Normal
NCV (In elder brother)	

MRI (PROBAND)



WHOLE EXOMW SEQUENCING IN PROBAND + SANGER SEQUENCING IN OTHER			
	Detected variants		
Proband	TPK1 Homozygous missense variant	PMP22 Heterozygous missense variant	BRCA2 Heterozygous nonsense variant
	Thiamine metabolism dysfunction syndrome 5 episodic encephalopathy type	Charcot-Marie-Tooth disease demyelinating type 1a	Breast cancer male susceptibility to
	VARIANT OF UNCERTAIN SIGNIFICANCE	VARIANT OF UNCERTAIN SIGNIFICANCE	PATHOGENIC
Elder brother	Homozygous	Not done	Not done
Parents	Heterozygous	Not done	Not done

MANAGEMENT GIVEN


Anti spasticity + Anti dystonia medication given + Oral thiamine (Poor compliance) was started in the proband → no improvement, clinical worsening

ACKNOWLEDGEMENT

Thank the patient and her family for their permission to share the details of their family and to cooperate through this difficult medical journey

CLINICAL SUSPICION

Significant Family history
Movement abnormality
Neuroregression
Episodic decompensation
Fast progressive



Neurotransmitter disorders
Neurodegenerative disorders
Mitochondrial disorders

DISCUSSION

Thiamine Metabolism Dysfunction Syndrome 5 (TMD5)

Childhood onset subacute progressive disorder
Initial development – can be Normal/ delayed
Episodes of decompensation during illness /stress with lactic acidosis
– Ataxia , dysarthria, dystonia, Psychomotor regression
Seizures ophthalmoplegia, nystagmus – less common
Biochemical feature: elevation of multiple organic acids especially 2-ketoglutaric acid.
– Plasma thiamine level can be normal or slightly reduced
– decrease in blood TPP
Neuroimaging : T2W Hyperintensity in basal ganglia + cerebellum (dentate)
Defects in TPK1 gene causing reduced / gain of activity of Thiamine phosphokinase 1
Early treatment with thiamine (100-500mg/day) + Biotin - improves psychomotor + movement disorder
Utility of ketogenic diet remains unclear
Late or no treatment → Poor prognosis

OTHER THIAMINE METABOLISM DEFECTS

	SLC19A2 Mutations - Rogers syndrome	SLC19A3 Mutation – Biotin Thiamine responsive basal ganglia disease	SLC25A19 Mutation- Defects of the mitochondrial thiamine pyrophosphate transporter	Nutritional deficits
Clinical criteria	Megaloblastic Anemia, thrombocytopenia, diabetes mellitus, and sensorineural deafness	Acute / Recurrent episodes of encephalopathy with dystonia, hypotonia, ataxia, bulbar dysfunction, seizures. Rarely rigidity + quadriparesis	Severe encephalopathy with progressive peripheral neuropathy OR Severe congenital microcephaly with brain malformation.	Later onset Neurological symptoms mimic inborn pyruvate oxidation deficiencies. Significant systemic findings
Biochemical features		Normal in blood but Low free thiamine in CSF/ fibroblast	Normal thiamine in blood	Low thiamine blood levels
Neuroimaging		Symmetrical T2W HI in caudate, putamen, thalamus + cortico/subcortical areas	Symmetrical T2W HI in caudate + putamen	Thalamus , periaqueductal region, mamillary body HI
Therapy	Thiamine responsive			

TAKE HOME MESSAGE

Rare but potentially treatable

Consider in patients with recurrent episodic encephalopathy and/or dystonia, increased blood lactate + basal ganglia and thalamic involvement on MRI

No specific biomarker hence molecular testing necessary

EARLY SUSPICION → EARLY DIAGNOSIS → EARLY TREATMENT = GOOD PROGNOSIS

Further studies required to understand the complete spectrum and optimize treatment.

REFERENCES

- Mayr JA, Freisinger P, Schlachter K, et al. Thiamine pyrophosphokinase deficiency in encephalopathic children with defects in the pyruvate oxidation pathway. Am J Hum Genet. 2011 Dec 9;89(6):806-12.
- Ortigoza-Escobar JD, Alfadhel M, Molero-Luis M, et al. Thiamine Deficiency Study Group. Thiamine deficiency in childhood with attention to genetic causes: Survival and outcome predictors. Ann Neurol. 2017 Sep;82(3):317-330.
- Ortigoza-Escobar JD, Molero-Luis M, Arias A, et al. Treatment of genetic defects of thiamine transport and metabolism. Expert Rev Neurother. 2016 Jul;16(7):755-63.
- Eckenweiller M, Mayr JA, Grünert S, Abicht A, et al. Treatment and Favorable Outcome in an Infant with Biallelic TPK1 Variants. Neuropediatrics. 2021 Apr;52(2):123-125.
- Rüsch CT, Wortmann SB, Kovacs-Nagy R, et al. Thiamine Pyrophosphokinase Deficiency due to Mutations in the TPK1 Gene: A Rare, Treatable Neurodegenerative Disorder. Neuropediatrics. 2021 Apr;52(2):126-132.
- Marcé-Grau A, Martí-Sánchez L, Baide-Mairena H, et al. Genetic defects of thiamine transport and metabolism: A review of clinical phenotypes, genetics, and functional studies. J Inher Metab Dis. 2019 Jul;42(4):581-597.